Healthcare Triangle, Inc. filings document material-event reporting, shareholder voting matters, capital-structure changes, acquisition records, and governance disclosures for a healthcare information technology company. Recent 8-K filings cover the company’s Nasdaq-listed common stock, emerging growth company status, board-approved share repurchase program, and the completed reverse stock split reflected in amendments to its certificate of incorporation.
The filing record also includes proxy materials for a special stockholder meeting and material-agreement disclosures tied to subsidiary transactions. An amended 8-K provides acquired-business financial statements and pro forma financial information for Teyamé 360 S.L. and Datono Mediación S.L., connecting transaction disclosures with HCTI’s broader AI, digital health, and customer-engagement platform activity.
Healthcare Triangle, Inc. (HCTI) stockholders approved amendments authorizing one or more reverse stock splits at ratios from 1-for-2 to 1-for-25; the board will determine the exact ratio, and the aggregate ratio may not exceed 1:25. Stockholders also approved, for Nasdaq Listing Rule 5635(d) purposes, any 20% Issuance the company makes below the Minimum Price and within the Nasdaq Parameters; an amendment removing reverse-split adjustments from the 2020 Stock Incentive Plan; and adjournment if needed to solicit additional proxies.
At the October 23, 2026 virtual meeting, holders of 20,257,026 shares were present or represented, approximately 53.69% of 37,730,008 common shares stated as issued and outstanding and entitled to vote. The reverse-split proposal received 20,163,583 votes for, 93,410 against and 33 abstentions. Voting shares included common stock and Series A Super Voting Preferred Stock.
Healthcare Triangle asks stockholders to authorize one or more reverse splits of its common stock at a ratio from 1-for-2 to 1-for-25, with the board choosing the final ratio and retaining discretion not to proceed. If approved and implemented, the aggregate ratio cannot exceed 1-for-25, and the split must take effect before the first anniversary of the special meeting. The company says it would not proportionally reduce authorized common shares, increasing the number available for future issuance.
A separate proposal seeks approval for future issuances under Nasdaq parameters: up to 250 million common shares, up to 250 million shares upon warrant exercise, a maximum issuance amount of $100 million, and a maximum market discount of 80%. The stated closing deadline is January 23, 2027. The company says such issuances would dilute existing stockholders. Another proposal would prevent the number of shares available for future awards under the 2020 Stock Incentive Plan from being adjusted for a reverse split; the amendment would end with the Plan on December 31, 2030.
The virtual special meeting is scheduled for October 23, 2026. Stockholders of record on October 5, 2026, may vote on these proposals and an adjournment proposal.
Healthcare Triangle, Inc. is asking stockholders to approve a reverse split of its common stock at a ratio from 1-for-2 to 1-for-25. If approved, the Board would select the final ratio and retain discretion to abandon the split. The company says the proposal is intended to help maintain its Nasdaq listing by addressing the $1.00-per-share minimum bid-price requirement. The proposal does not include a proportional reduction in authorized common shares.
A separate proposal seeks approval for future issuances below the Nasdaq “Minimum Price” and within stated parameters: a maximum of 250,000,000 common shares issuable, 250,000,000 shares issuable upon warrant exercise, a $100,000,000 maximum issuance amount and an 80% maximum discount to market. Healthcare Triangle says completed issuances would dilute existing holders, including their voting power over time. Stockholders are also asked to approve a plan amendment so the reserve for future awards is not reduced in a reverse split; the amendment is subject to stockholder approval, and the plan ends December 31, 2030. The special meeting is virtual, and October 5, 2026 is the record date for voting.
Healthcare Triangle, Inc. (HCTI) received a Nasdaq Staff Delisting Determination after Nasdaq notified it that its common stock did not meet the $1.00-per-share minimum closing bid price. Nasdaq said HCTI is ineligible for the normal 180-calendar-day compliance period because it effected reverse stock splits over the prior two years with a cumulative ratio of 1-for-14,940.
HCTI intends to request a hearing by October 8, 2026. Without an appeal by then, trading would be suspended at the opening of business on October 12, 2026, and Nasdaq would file a Form 25-NSE to remove the securities from listing and registration. A hearing request would stay the suspension and Form 25-NSE filing pending the Panel’s decision and the expiration of any additional extension period granted by the Panel. The notice has no immediate effect, and HCTI common stock continues to trade under HCTI. HCTI intends to present a compliance plan that may include a reverse stock split if necessary; the Panel may not grant continued listing, and HCTI may not regain compliance within any additional period.
Healthcare Triangle, Inc. (HCTI) amended its Form S-1 registration statement for resale by Hudson Global Ventures, LLC or its assignees of up to 28,000,000 common shares; the amendment registers no additional securities. The registered amount comprises up to 27,950,000 shares issued or issuable to Hudson under an equity line of credit (ELOC) and 50,000 shares issuable upon exercise of a five-year warrant with a $0.00001 per-share exercise price.
Hudson receives proceeds from its resales, while Healthcare Triangle may receive up to $50,000,000 in aggregate gross proceeds from share sales to Hudson that the company elects to make, subject to agreement conditions. The agreement covers an approximately 36-month period beginning June 12, 2026. Each Put Notice may cover at least $25,000 and no more than the lesser of $250,000 or 200% of average daily trading volume over the prior three trading days. Shares sold to Hudson may not exceed a 4.99% beneficial-ownership limit, and stockholder approval is required for aggregate ELOC issuance above 405,353 shares.
Healthcare Triangle, Inc. (HCTI) amended its Equity Purchase Agreement with Hudson Global Ventures, LLC on September 22, 2026. The amendment reduces the maximum amount that may be sold under each Put Notice from $2,500,000 to $250,000 and raises the minimum price per share threshold from $0.01 to $0.10, subject to adjustments for specified stock and rights transactions.
After a Change of Control Transaction, HCTI no longer has the right to deliver Put Notices. The amendment also redefines “Purchase Price” and “Valuation Period”; all other agreement terms remain in effect.
Healthcare Triangle, Inc. (symbol: HCTI) is the issuer of record for a Form 8-K filing submitted to the SEC.
Healthcare Triangle, Inc. reported sharply higher revenue but significantly larger losses for the period ended June 30, 2026. Net revenue for the quarter rose to $9,193 from $3,558 a year earlier, and for the first six months to $19,046 from $7,263, driven primarily by the newly acquired AI-powered Customer Engagement Services segment (Teyame and Datono).
Despite growth, profitability weakened. The company posted a six-month loss from operations of $7,696 versus $2,757 in 2025 and a six-month net loss of $10,615 versus $3,068. Operating cash flow was negative $7,697, and cash and cash equivalents declined to $1,906 from $7,625 at year-end 2025.
Total assets increased to $73,640 (from $22,736) as a result of the Teyame/Datono acquisition, including $54,825 of other intangible assets and $2,946 of goodwill. The capital structure now includes $8,103 of bank debt, $3,724 of 2026 convertible notes at fair value, and $49,099 of stockholders’ equity, with new Series C preferred stock and common stock consideration tied to the acquisition. Management acknowledges past losses but concludes that existing net assets, a stockholder-approved $50,000 Equity Line of Credit, and an at-the-market program provide sufficient liquidity for at least twelve months.
Healthcare Triangle, Inc. reported unregistered issuances of common stock tied to two legacy M&A transactions. On July 28, 2026 it issued 9,718,373 shares in connection with its acquisition involving Teyame AI LLC and 2,828,167 shares under a Securities Exchange Agreement with SecureKloud Technologies Ltd., for a total of 12,546,540 new shares. These issuances were approved by shareholders and made under Section 4(a)(2) of the Securities Act and/or Regulation D, with no underwriters or commissions.
According to management, these legacy transactions increased common shares outstanding to 14,644,322 as of the close of business on July 28, 2026 and raised the company’s Market Value of Listed Securities to approximately $23,870,244, based on a $1.63 share price. This provides a buffer over Nasdaq’s newly approved $5 million minimum Market Value of Listed Securities continued listing standard, which the company says strengthens its compliance position.